Canaccord Genuity Maintains a Buy on Inventiva (IVA) With a $20 Price Target

Inventiva S.A. (NASDAQ:IVA) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. Analyst Edward Nash from Canaccord Genuity maintained a Buy rating on Inventiva S.A. (NASDAQ:IVA) on June 5, keeping the price target at $20.00.

The rating was based on several factors, including the potential of lanifibranor, the company’s lead asset in the MASH space. Lanifibranor’s oral administration and direct anti-fibrotic effects distinguish it from other treatments in development, with a primary focus on liver fat reduction.

A research scientist in an idiopathic pulmonary fibrosis laboratory, carrying out clinical trials.

The analyst also reasoned that Lanifibranor can be used in conjunction with other treatments, including GLP-1s and SGLT2 inhibitors. This factor is a significant boost to its appeal, especially when considering the high prevalence of type 2 diabetes in MASH patients.

Nash stated that the drug is progressing well, which can be corroborated by the completion of full enrollment in the Phase III NATiV3 trial and the anticipated top-line data in H2 2026. Major pharmaceutical companies are also showing increasing interest in the MASH space, further supporting the optimistic outlook for Inventiva S.A. (NASDAQ:IVA).

Inventiva S.A. (NASDAQ:IVA) is a clinical-stage biopharmaceutical company that develops oral small-molecule therapies to treat non-alcoholic steatohepatitis or NASH. It also develops therapies for other diseases with considerable unmet medical needs.

While we acknowledge the potential of IVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.